BioNotebook: Four pipeline updates; Sage, Acadia, ArQule and GTx
This article was originally published in Scrip
Executive Summary
Sage Therapeutics will talk to the US FDA about the design of a Phase III pivotal trial for SAGE-547 in the treatment of super refractory status epilepticus (SRSE), which the company expects to initiate during the first half of 2015, based on positive results from an ongoing Phase I/II clinical trial.